Novartis AG / Ionis Pharmaceuticals, Inc. / Akcea Therapeutics, Inc.
2016 · Licensing/Option · $1.4B · Complete
Announcement Sentiment
100
Strongly positive
Novartis entered a worldwide option and collaboration agreement with Ionis Pharmaceuticals and its Akcea Therapeutics subsidiary on two Phase 1/2a antisense cardiovascular candidates (AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx). Near-term payments of $175M total ($75M upfront + $100M equity in Ionis). Up to $600M (APO(a)) and $530M (APOCIII) in development/commercial milestones plus tiered royalties topping 20%. Novartis to fund Phase 3 CV outcomes trial upon option exercise.
Key facts
AnnouncedNov 29, 2016
ClosedFeb 25, 2019
Deal value$1.4B
Deal typeLicensing/Option
Therapeutic areaCardiovascular risk reduction in patients with elevated Lp(a) and ApoCIII
IndicationsCardiovascular risk reduction in patients with elevated Lp(a) and ApoCIII